A phase 3 trial to evaluate the safety and efficacy of the specific immunotherapy, recombinant idiotype conjugated to KLH [keyhole limpet haemocyanin] (GTOP 99) with GM-CSF [granulocyte-macrophage colony-stimulating factors], compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma

Trial Profile

A phase 3 trial to evaluate the safety and efficacy of the specific immunotherapy, recombinant idiotype conjugated to KLH [keyhole limpet haemocyanin] (GTOP 99) with GM-CSF [granulocyte-macrophage colony-stimulating factors], compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2008

At a glance

  • Drugs GTOP 99 (Primary)
  • Indications B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 May 2008 Status change
    • 16 Apr 2008 Status change from in progress to completed
    • 16 Apr 2008 Results presented at AACR in 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top